PCSK9 Inhibitor
Evolocumab / Alirocumab
PCSK9 inhibitors are the most potent lipid-lowering drugs available, cutting LDL-C and ApoB by 50-60% on top of a statin. Subcutaneous injections every 2-4 weeks. FOURIER and ODYSSEY OUTCOMES proved they reduce cardiovascular events in high-risk patients.
PCSK9 monoclonal antibody (subcutaneous injection)Prescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
Loss-of-function mutations in PCSK9 confer lifelong low LDL-C and dramatic protection from coronary disease - a natural experiment that inspired the entire drug class. Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that inactivate circulating PCSK9, allowing hepatic LDL receptors to recycle and clear more ApoB-containing particles. FOURIER (NEJM 2017) and ODYSSEY OUTCOMES (NEJM 2018) demonstrated cardiovascular event reductions in patients with established ASCVD on background statin. The lipid effects are unmatched: LDL-C drops 50-60% beyond statin, ApoB falls in parallel, and Lp(a) decreases 20-30% - the only widely available drug class that touches Lp(a) meaningfully until pelacarsen and olpasiran arrive. Side effects are minimal beyond injection site reactions; the EBBINGHAUS substudy ruled out cognitive harm. The historical barrier was cost (over 14,000 USD per year at launch), now reduced to around 5,800 USD with manufacturer rebates. For high-risk men or those with elevated Lp(a), PCSK9 inhibition has redefined what is achievable in cardiovascular prevention.
Uses
Label uses (approved)
- Adjunct to diet plus maximally tolerated statin in heterozygous and homozygous familial hypercholesterolemia
- Established ASCVD requiring additional LDL-C lowering
- Statin-intolerant patients with very high cardiovascular risk
Off-label (educational only)
- Aggressive ApoB lowering for primary prevention in high lifetime risk — Achieves LDL-C reductions of 50-60% on top of statin; lifetime ApoB exposure is the dominant ASCVD driver
- Lp(a)-elevated patients — PCSK9 inhibitors are one of the few interventions that reduce Lp(a) by 20-30%, though pelacarsen and olpasiran will be more selective when approved
Dosing
Label dose
Evolocumab 140 mg SC every 2 weeks or 420 mg SC monthly; Alirocumab 75-150 mg SC every 2 weeks
Off-label / biohacker dose
Same as label; some clinicians use monthly evolocumab 420 mg as the default for convenience
Titration: No titration required for evolocumab; alirocumab may be uptitrated from 75 to 150 mg if LDL-C target not achieved at 4-8 weeks. Inject SC into abdomen, thigh, or upper arm. Allow autoinjector to reach room temperature 30 minutes before use. Check lipids at 4-8 weeks.
When to take: Every 2 weeks or monthly depending on regimen. Consistent day of week recommended. Subcutaneous self-injection.
Side effects & warnings
Common
- Injection site reactions (erythema, pain, bruising)
- Nasopharyngitis
- Influenza-like symptoms
- Back pain
- Myalgia (uncommon)
Uncommon but serious
- Hypersensitivity reactions
- Nasal congestion
- Urinary tract infection
- Mild transaminitis (rare)
Serious warnings
Serious hypersensitivity reactions including angioedema reported rarely. Contraindicated in patients with prior hypersensitivity. Long-term cognitive safety reassuring in EBBINGHAUS substudy of FOURIER.
Biomarkers affected
apob
decrease50-60% ApoB reduction on top of statin; upregulates hepatic LDL receptors via PCSK9 inactivation
Evidence: strong
ldl c
decrease50-60% LDL-C reduction on top of statin; FOURIER and ODYSSEY OUTCOMES
Evidence: strong
lp a
decrease20-30% Lp(a) reduction; one of few available interventions affecting Lp(a)
Evidence: moderate
Monitoring
Lipid panel + ApoB at 4-8 weeks then every 6-12 months; injection site assessment
The honest risk picture
PCSK9 inhibitors have one of the cleanest long-term safety profiles in cardiology, but several considerations remain. The most common complaints are injection site reactions - erythema, pain, or bruising - typically mild and self-limited. Pre-warming the autoinjector and rotating between abdomen, thigh, and upper arm reduces these. Influenza-like symptoms and nasopharyngitis occur in 5-10% of patients. Serious hypersensitivity reactions including angioedema have been reported rarely; prior reaction is a contraindication. Cognitive safety was specifically evaluated in EBBINGHAUS (a FOURIER substudy) and showed no decline despite LDL-C levels below 25 mg/dL in many patients - addressing concerns about extreme lipid lowering. Long-term safety data now extend beyond 8 years. Cost remains the primary barrier in many markets, though manufacturer assistance programs make the drug accessible to most insured patients. Subcutaneous self-injection requires patient comfort with needles, though the autoinjectors are designed to be one-button operations. Pregnancy data are limited; the drug is avoided during pregnancy because of theoretical concerns about fetal LDL-C, though no human teratogenicity has been documented.
Practical context
Cost (US, retail)
$800/mo
Legality
FDA-approved 2015; Rx required. Specialty pharmacy distribution. Patient assistance programs available.
Interactions
false
FAQ
How much does a PCSK9 inhibitor lower LDL-C?+
50-60% on top of background statin therapy. Combined with high-intensity statin and ezetimibe, total LDL-C reductions can exceed 75%.
Will insurance cover it?+
Increasingly yes for established ASCVD or familial hypercholesterolemia, less often for primary prevention. List price was historically over 14,000 USD per year but has fallen to approximately 5,800 USD with discounts. Patient assistance programs are widely available.
Is the injection painful?+
Most patients tolerate it well. Pre-warming the autoinjector and rotating sites reduces discomfort. The thigh is generally less sensitive than the abdomen.
Does it lower Lp(a)?+
Yes, by 20-30% on average - one of the only currently available interventions to do so.
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.